

REMARKS

Claims 1 and 3-8 are pending. Claims 2 and 9 have been canceled.

THE REJECTIONS UNDER 35 U.S.C. §112:

Claims 1 and 3-8 were rejected under 35 U.S.C §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicants respectfully traverse.

Specifically, The Examiner has questioned whether the recitation of variable G in proviso c “is part of the proviso or a new choice for G.” (December 14, 2006 Office Action, Page 2).

Applicants respectfully inform the Examiner that this recitation of variable G is as part of proviso c and not a new choice for G.

Further, The Examiner has questioned applicants’ inclusion of variable “p” in the last line of Claim 1 as “there appears to be no p variable in claim 1 or its dependent claims 3-8.” (December 14, 2006 Office Action, Page 2). Applicants respectfully direct the Examiner’s attention to proviso c, variable R₁₃ which may be “S(O)_pR₁₅”.


In light of the above comments, applicants respectfully request the Examiner withdraw these rejections.

CONCLUSION

No fee is believed due for the filing of this Amendment; however, should any fee be found to be due please charge said fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. In view of the foregoing, applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000


Sammy G. Duncan, Jr.
Attorney for Applicant
Reg. No. 46,675
Phone: 609-252-6270
Date: March 14, 2007